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Abstract
AIM: To investigate the risk factors for Clostridium-
difficile -associated diarrhea (CDAD) recurrence, and its 
relationship with proton pump inhibitors (PPIs). 
METHODS: Retrospective data of 125 consecutive 
hospitalized patients diagnosed with CDAD between 
January 2006 and December 2007 were collected by 
medical chart review. Collected data included patient 
characteristics at baseline, underlying medical disease, 
antibiotic history before receiving a diagnosis of CDAD, 
duration of hospital stay, severity of CDAD, concurrent 
treatment with PPIs, laboratory parameters, response to 
CDAD therapy, and recurrence of disease within 90 d of 
successful treatment. Various clinical and laboratory pa-
rameters were compared in patients in whom CDAD did 
or did not recur.
RESULTS: Of the 125 patients (mean age, 67.6 ± 
13.9 years) that developed CDAD, 98 (78.4%) did not 
experience recurrence (non-recurrent group) and 27 
(21.6%) experienced one or more recurrences (recur-
rent group). Prior to the development of CDAD, 96% 
of the 125 patients were prescribed antibiotics, and 
56 (44.8%) of the patients received PPIs. Age older 
than 65 years (P  = 0.021), feeding via  nasogastric 
tube (NGT) (P  = 0.045), low serum albumin level (P  
= 0.025), and concurrent use of PPIs (P  = 0.014) 
were found to be risk factors for CDAD recurrence by 
univariate analysis. However, sex, length of hospital 
stay, duration and type of antibiotics used, severity of 
disease, leukocyte count and C-reactive protein (CRP) 
were not associated with risk of CDAD recurrence. On 
multivariate analysis, the important risk factors were 
advanced age (> 65 years, adjusted OR: 1.32, 95% 
CI: 1.12-3.87, P  = 0.031), low serum albumin level (< 
2.5 g/dL, adjusted OR: 1.85, 95% CI: 1.35-4.91, P  = 
0.028), and concurrent use of PPIs (adjusted OR: 3.48, 
95% CI: 1.64-7.69, P  = 0.016). 
CONCLUSION: Advanced age, serum albumin level < 
2.5 g/dL, and concomitant use of PPIs were found to 
be significant risk factors for CDAD recurrence. 
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INTRODUCTION
Clostridium difficile is a spore-forming Gram-positive anaer-
obic bacillus and is the most common cause of  hospital-
acquired diarrhea[1]. C. difficile infection occurs when a sus-
ceptible host ingests spores, which then colonize the large 
bowel and release endotoxin. Specific antibiotic treatments 
with metronidazole or vancomycin show high levels of  
efficacy and reduce morbidity and mortality[2]. However, 
although initial response rates to antibiotic therapy exceed 
90%, 10%-30% of  patients experience C. difficile-associ-
ated diarrhea (CDAD) recurrence[3], which increases the 
cost of  medical care, and causes re-hospitalization, com-
plications, and mortality[4]. The complications of  recurrent 
CDAD included toxic megacolon, septicemia, and C. diffi-
cile-associated arthritis. Furthermore, the average length of  
stay due to admission for recurrent CDAD among outpa-
tients has been reported to be 8.8 d (range, 3-26)[5,6]. It has 
been reported that the elderly, and patients with chronic 
renal failure, multiple previous CDAD episodes, or a high 
level of  white blood cell count (≥ 15 × 109/L), and those 
that continue to use systemic antibiotics after a diagnosis 
of  CDAD, are at high risk of  recurrence[7,8].
Gastric acid inhibits the germination of  ingested 
spores and the survival of  C. difficile, and recent studies 
have found that gastric acid suppressive agents, such as 
PPIs, increase the risk of  CDAD development in hospi-
talized patients[9,10]. However, relatively few studies have 
attempted to determine whether the use of  gastric acid 
suppressive agents is associated with an elevated risk of  
CDAD recurrence[11,12].
The purpose of  this study was to determine the risk 
factors of  CDAD recurrence in hospitalized patients, and 
to investigate the relation between PPIs use and CDAD 
recurrence. 
MATERIALS AND METHODS
Identification of subjects and collection of clinical data
This retrospective study was performed at Seoul Nation-
al University Boramae Hospital, a 500-bed teaching hos-
pital, between January 1, 2006 and December 31, 2007. 
The medical records of  all patients diagnosed with 
CDAD based on typical symptoms, that is, three or more 
bowel movements per day, abdominal pain, fever, leuko-
cytosis at least 3 d after admission, and a positive ELISA 
result for C. difficile toxins A and B (Wampole TOX A/B 
Quic Check, Techlab, Blacksburg, VA, USA). The exclu-
sion criteria applied were: age < 18 years, CDAD during 
the previous 3 mo, failure to complete at least 7 d of  an-
tibiotic therapy, a diagnosis of  CDAD within 3 d of  ad-
mission, or the presence of  any other cause of  diarrhea, 
such as, laxative use, the presence of  another infectious 
pathogen, and inflammatory bowel disease. 
Medical records included the following information: 
age; sex; type of  underlying disease; duration, number and 
type of  antibiotics prescribed before diagnosis of  CDAD; 
hematological and biochemical parameters; CDAD sever-
ity; PPI use; specific therapy used to treat CDAD; time to 
resolution of  CDAD symptoms; and disease recurrence 
within 90 d of  cure. CDAD was considered severe if  two 
or more of  the following factors were present: (1) a fre-
quency of  stool of  > 10/d; (2) fever (> 38.3℃); and (3) a 
leukocyte count of  > 15 000 cells/mm3. PPI use was de-
fined as at least 3 d treatment before the development of  
CDAD and continuous use thereafter.
In the majority of  patients, oral metronidazole for 
10-14 d was initially administered. Vancomycin was re-
served for those that did not respond to metronidazole or 
had severe CDAD. The main causes of  antibiotic prescrip-
tion were pneumonia, urinary tract infection, postopera-
tive wound infection, osteomyelitis, and cellulitis. Patients 
were classified into two groups based on recurrence with-
in 90 d of  cure (the recurrent and non-recurrent groups). 
Patients were regarded as cured when stool frequencies 
and consistencies were normal for at least three consecu-
tive days. Recurrence was defined as diarrhea recurrence 
with a positive ELISA result for cytotoxin A, within 90 d 
after therapy completion, and the complete resolution of  
signs and symptoms. Patients were monitored for recur-
rence throughout this 90-d period.
Statistical analysis
SPSS 12.0 software (SPSS Inc., Chicago, IL, USA) was 
used for the statistical analysis. Patients were divided into 
recurrent and non-recurrent groups. Data are presented 
as mean ± SD or percentage frequencies. Student’s t 
test, χ2 test and Fisher’s exact test were used to analyze 
continuous and categorical variables. Logistic regression 
analysis was used to determine the effects of  continuous 
variables on recurrence. For all analyses, P < 0.05 was 
considered significant. This study was approved by the 
institutional review board of  Seoul National University 
Boramae Hospital.
RESULTS
A total of  125 patients who received full course therapy 
for CDAD were included in this study. There were 57 
(45.6%) men and 68 (54.4%) women, and mean patient 
age was 67.6 years (range 35-92). One hundred and 
twenty (96%) were prescribed antibiotics before CDAD 
was diagnosed. The most common antibiotics adminis-
tered were cephalosporins (80.8%), clindamycin (25.6%), 
penicillin analogues (20%), and quinolones (19.2%). Five 
patients (4%) did not receive antibiotics prior to diag-
nosis of  CDAD, and 81 (64.8%) were treated with more 
than one antibiotic. Forty-eight (38.4%) patients had dia-
betes, 41 (32.8%) had malignant disease, and 17 patients 
(13.6%) had chronic renal failure. Thirty-five patients 
(28%) were fed via an NGT before diagnosis. Of  the 
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125 subjects, 56 (44.8%) received PPIs for ≥ 3 d. One 
hundred and thirteen (90.4%) were initially treated with 
metronidazole, and 12 (9.6%) with vancomycin.
Of  the 125 study subjects, 27 (21.6%) experienced dis-
ease recurrence within 90 d after cure, and the remaining 
98 (78.4%) did not experience recurrence. The recurrence 
rate among patients treated with metronidazole was no 
different from that among patients treated with vancomy-
cin (21.2% vs 16.7%). Univariate analysis showed that five 
parameters were significantly associated with recurrence 
(Table 1). Patients aged ≥ 65 years were found to be more 
likely to develop recurrence than those < 65 years (59.3% 
vs 31.6%, P = 0.021). Patients fed via an NGT were also 
more likely to develop recurrence (48.1% vs 23.5%, P 
= 0.045). The mean serum albumin level at the time of  
CDAD diagnosis was lower in patients with recurrence 
than in patients without recurrence (2.3 ± 0.5 g/dL vs 3.1 
± 0.4 g/dL, P = 0.028). Furthermore, significantly more 
patients in the recurrent group received concurrent PPIs 
therapy (63.0% vs 39.8%, P = 0.014). However, sex, length 
of  hospital stay, duration of  antibiotics used before diag-
nosis of  CDAD, the presence of  diabetes mellitus or renal 
failure, severity of  CDAD, leukocyte count, hemoglobin 
and CRP levels were not found to be associated with an 
increased risk of  recurrence. 
Multivariate analysis showed that age > 65 years (OR: 
1.32, 95% CI: 1.12-3.87, P = 0.031), serum albumin level 
of  < 2.5 g/dL (OR: 1.85, 95% CI: 1.35-4.91, P = 0.028), 
and concurrent use of  PPIs (OR: 3.48, 95% CI: 1.64-7.69, 
P = 0.016) were associated with the risk of  recurrence 
(Table 2). 
Table 3 summarizes antibiotic use before CDAD was 
diagnosed. The mean number of  antibiotic types prescribed 
to patients was not found to be a risk factor for recurrence 
(2.58 in the recurrent group vs 2.43 in the non-recurrent 
group, P = 0.56). Furthermore, the two study groups were 
similar in terms of  exposure to high-risk antibiotics, such 
as, clindamycin, cephalosporins, or quinolones.
DISCUSSION
Recurrent CDAD is one of  the most difficult problems 
related to C. difficile infection. Despite an initial successful 
response in more than 90% of  patients, CDAD recurs in 
15%-30%[13,14]. In a previous study of  124 CDAD patients, 
24% experienced recurrence[15], which concurs with the 
20.8% observed in the present study. Patients treated with 
metronidazole (21.2%) had a greater tendency to recur 
than patients treated with vancomycin (16.7%), but this 
was not significant (P = 0.09). Studies have shown that 
the rates of  treatment failure and recurrence are greater 
for patients treated with initial metronidazole than for 
patients treated with vancomycin, especially since 2000[16]. 
Because of  its low cost and of  concerns about vancomy-
cin-resistant enterococci, metronidazole is recommended 
as first-line therapy. However, our finding that 21% of  
patients initially treated with metronidazole experienced 
recurrence suggests that vancomycin might be helpful as 
a first-line treatment in patients with multiple risk factors 
for recurrent CDAD. Although the pathogenesis of  recur-
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Table 1  Univariate analysis of risk factors for recurrence of 
Clostridium-difficile -associated diarrhea (mean ± SD)  n  (%)
Recurrence 
group  




(n  = 98)
P  value
Age (≥ 65 yr) 16 (59.3) 31 (31.6)  0.021a
Female 15 (55.6) 53 (54.1) 0.905
Length of hospital stay (d) 36.5 ± 9.7 32.8 ± 8.5 0.152
Duration of antibiotics used (d) 13.1 ± 6.8 12.2 ± 5.8 0.105
Admission from institution   6 (22.2) 17 (17.4) 0.379
Severe CDAD 13 (48.2) 30 (30.6) 0.156
Comorbidities                   
   Diabetes mellitus 11 (40.7) 37 (37.8) 0.572
   Malignancy 10 (37.1) 31 (31.6) 0.560
   Renal failure 5 (18.5) 12 (12.3) 0.215
Active tuberculosis 2 (7.4) 6 (6.1) 0.719
NGT feeding 13 (48.1) 23 (23.5)  0.045a
WBC count, (mean) × 103/mm3 15.1 ± 9.7 12.3 ± 8.1 0.413
WBC count > 15 × 103/mm3 (44.4) (40.8)
Hb (g/dL) 10.9 ± 1.9 11.4 ± 1.6 0.279
Serum albumin (g/dL)   2.3 ± 0.5   3.1 ± 0.4  0.025a
Serum albumin < 2.5 g/dL (59.3) (36.7)
Creatinine (mg/dL)   1.5 ± 1.4   1.2 ± 1.6 0.513
C-reactive protein (g/dL)   7.3 ± 4.8   5.6 ± 4.5 0.579
Use of PPIs 17 (63.0) 39 (39.8)  0.014a
aP < 0.05. CDAD: Clostridium-difficile-associated diarrhea; WBC: White 
blood cells; NGT: Nasogastric tube.
Table 2  Multivariate analysis of risk factors for recurrence of 
Clostridium-difficile -associated diarrhea
Risk factor Adjusted OR 95% CI P  value
Age (≥ 65 yr) 1.32 1.12-3.87  0.031a 
Low serum albumin of < 2.5 g/dL 1.85 1.35-4.91  0.028a
Concurrent use of PPI 3.48 1.64-7.69  0.016a
NGT feeding 1.25 0.91-2.65 0.068
aP < 0.05. NGT: Nasogastric tube; PPI: Proton pump inhibitor.
Table 3  Comparison of antibiotics used before diagnosis 
of Clostridium-difficile -associated diarrhea between non-
recurrent and recurrent group (mean ± SD)  n  (%)
Type of antibiotics used Non-recurrent 
CDAD 
(n  = 98)
Recurrent 
CDAD 
(n  = 27)
P  value
No. of antibiotics used 2.58 ± 0.9 2.43 ± 0.8 0.560
No antibiotics 4 (4.1) 1 (3.7) 0.638
1 antibiotics 28 (28.6)   9 (33.3) 0.497
≥ 2 antibiotics 64 (65.3) 19 (70.4) 0.435
Penicillin analogue 19 (19.4)   6 (22.2) 0.561
Cephalosporin 79 (80.6) 22 (81.4) 0.613
Clindamycin 26 (26.5)   6 (22.2) 0.265
Quinolone 17 (17.3)   7 (25.9) 0.217
Macrolide 8 (8.2) 2 (7.4) 0.691
Carbapenem 11 (11.2)   5 (18.5) 0.215
Metronidazole 6 (6.1) 2 (7.4) 0.563
Vancomycin 3 (3.1) 1 (3.7) 0.729
CDAD: Clostridium-difficile-associated diarrhea.
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rence is poorly understood, several risk factors have been 
described. The important risk factors were advanced age, 
longer hospital stay, continued use of  antibiotics for the 
treatment of  non-C. difficile diarrhea after a first episode 
of  CDAD, inadequate antitoxin antibody response, persis-
tent disruption of  colonic flora, and concomitant receipt 
of  antacid medications[17-19].
Several studies have reported that agents that sup-
press gastric acid secretion, especially PPIs, increase the 
risk of  CDAD development[20-22]. According to one study, 
the adjusted risk ratios for CDAD development for PPIs 
and H2-receptor antagonist (H2RA) usage are 2.9 (95% 
CI: 2.4-3.4) and 2.0 (95% CI: 1.6-2.7), respectively. How-
ever, another study on the relationship between CDAD 
development and exposure to acid suppressive therapy in 
hospitalized patients has revealed an association with PPIs 
(OR: 3.6, 95% CI: 1.7-8.3) but not with H2RAs. In the 
present study, we found that PPI use was a significant risk 
factor of  CDAD recurrence, which is in line with previ-
ous reports. In one study of  140 CDAD patients treated 
between 2004 and 2005, those receiving PPIs were found 
to be 4.17 times more likely to recur, which is greater than 
the OR found in the present study[11]. This result may 
be due to differences between study populations. In the 
study conducted by Cadle et al[11], most patients (98.6%) 
were men and the proportion of  patients who received 
PPIs was greater than in the present study (69% vs 55%). 
In a recent meta-analysis, continued use of  non-C. difficile 
antibiotics after a diagnosis of  CDAD (OR: 4.23, 95% CI: 
2.10-8.55), concomitant receipt of  antacid medication (OR: 
2.15, 95% CI: 1.13-4.08), and older age (OR: 1.62, 95% 
CI: 1.11-2.36) were found to be significantly associated 
with the risk of  CDAD recurrence[12]. However, in this 
meta-analysis, PPIs and H2RAs were not differentiated, 
and thus, their specific effects on CDAD recurrence could 
not be evaluated. 
The mechanisms by which acid suppressive agents 
increase the risk of  CDAD development and recurrence 
are poorly understood[23]. However, although the spores 
of  C. difficile are resistant to gastric acid, it has been sug-
gested the survival and germination of  C. difficile spores 
are greater at lower acidity, and that higher gastric pH in-
creases vegetative bacteria counts in the small and large 
intestine[24]. Previous studies have found that gastric acid 
suppression increases stomach and small bowel coloniza-
tion by bacteria and C. difficile[25,26]. Alternatively, it is also 
possible that PPIs directly affect host immune function, 
and thus, increase susceptibility to CDAD recurrence[27].
In the present study, age was found to be a risk fac-
tor for recurrence. A retrospective study of  hospitalized 
patients in Quebec also has shown that patients aged > 
65 years have a higher risk of  CDAD recurrence after 
metronidazole and vancomycin therapy[28]. The reason 
why advanced age increases the risk of  recurrence may 
be that these patients have comorbidities and are likely 
to be administered additional antibiotics for concomitant 
infections. A low serum albumin level was also found to 
be a significant risk factor for recurrence in our study. 
Hypoalbuminemia reflects a poor nutritional status, 
and may compromise immune response by diminishing 
antibody response to C. difficile. In one study, patients 
with recurrent disease were found to have significantly 
lower levels of  IgG to toxin A than patients that did not 
recur[29]. Later increased serum levels of  IgM and IgG 
to toxin A are known to be associated with a substantial 
reduction in the risk of  CDAD recurrence[16]. 
In contrast to previous reports, we found no relation-
ship between renal failure, leukocytosis, or CDAD severity 
and recurrence. However, we defined renal failure based 
on creatinine level alone, rather than on creatinine clear-
ance, and this does not reflect the range of  renal failure. 
With regard to leukocytosis and disease severity, a signifi-
cant proportion of  our study subjects were elderly, due to 
a failure to increase leukocytes in response to infection in 
some elderly patients, which may have influenced our re-
sults. Previous reports have shown that clindamycin, peni-
cillin and cephalosporin use is an important risk factor for 
CDAD development, and recently, ciprofloxacin use also 
has been found to be a significant risk factor for CDAD 
in hospitalized patients[30-32]. In the present study, however, 
antibiotic use prior to CDAD was similar in our two pa-
tient groups, and this suggested that type and number of  
antibiotics used prior to CDAD might have influenced 
CDAD development, but not CDAD recurrence. 
This study had several limitations that should be con-
sidered. First, the study was inherently limited by its retro-
spective nature, and in particular, stool cultures were not 
conducted, which prevented our determining whether re-
current CDAD was due to reinfection or relapse. Second, 
the confidence interval regarding the use of  PPIs as a risk 
factor for recurrent CDAD was relatively large, which was 
probably due to the small number of  patients enrolled in 
this study. Third, actual compliance to PPIs could not be 
assessed beyond the prescription data contained in medi-
cal charts. 
In conclusion, older age (> 65 years) and a low serum 
albumin level (< 2.5 g/dL) were identified as risk factors 
for CDAD recurrence. The concomitant use of  PPIs fur-
ther enhanced the risk of  recurrence. Of  these risk fac-
tors, the use of  PPIs is modifiable, and thus, it is appropri-
ate to review constantly the necessity for concomitant use 
of  PPIs in patients with CDAD. Prevention of  unwar-
ranted PPI therapy may be helpful in reducing the risk of  
recurrence, and additional larger studies are necessary in 
order to understand better the relationship between PPI 
use and CDAD recurrence. 
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The incidence and severity of Clostridium-difficile-associated diarrhea (CDAD) 
is increasing worldwide due to increased use of antibiotics and the introduction 
of hypervirulent strains. After successful initial therapy, approximately 10%-30% 
of patients experience symptomatic recurrence. Recurrence of CDAD causes 
increasing cost of medical care, re-hospitalization and complications. It is known 
that older patients, patients with chronic renal failure and multiple episode of 
previous CDAD are high risk groups for disease recurrence. Recent reports have 
suggested that the use of proton pump inhibitors (PPIs) is associated with CDAD 
recurrence in hospitalized patients, although the results appear to be conflicting. 
The objective of this study was to evaluate the risk factors for CDAD recurrence 
and to investigate the relationship of PPI use and recurrence of CDAD. 
 COMMENTS
3576 July 28, 2010|Volume 16|Issue 28|WJG|www.wjgnet.com
Kim JW et al . PPIs and CDAD recurrence
Research frontiers
Risk factors that are associated with CDAD recurrence and the association be-
tween use of PPIs and CDAD recurrence have been hot topics in recent studies. 
Of the 125 patients that developed CDAD, 98 did not experience recurrence and 
27 experienced one or more recurrences. The important risk factors for CDAD 
recurrence were age > 65 years, low serum albumin level < 2.5 g/dL, and use of 
PPIs.
Innovations and breakthroughs
This study showed that advanced age, low serum albumin level and use of 
PPIs were associated with increased risk of CDAD recurrence. 
Applications 
This retrospective analysis of the risk factors for CDAD recurrence imply that 
avoidance of unwarranted PPI therapy may be helpful in reducing the risk of 
CDAD recurrence. 
Peer review
This is a timely study extending present knowledge that PPIs are a risk factor 
for C. difficile reinfection. 
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